During a press conference Tuesday at the International AIDS Conference in Vienna, Anthony Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases at NIH, describes the Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial. The study is testing the safety and efficacy of microbicide gel containing the ARV drug tenofovir, and oral tablets containing tenofovir or a combination of tenofovir and emtricitabine known by the brand name Truvada.
Study: A sterile syringe program already in place would have significantly reduced Scott County HIV incidence
Once outbreak was recognized, program put in place reduced number of ongoing transmissions, modeling shows In 2015, when 181 of rural Scott County, Indiana’s 24,000 residents […]
SYDNEY – When Merinda Sebayang was undergoing treatment for multidrug-resistant TB in Indonesia – a nation with the third highest tuberculosis burden in the world after […]
A randomized, multi-country clinical trial testing a regimen for treating drug-resistant tuberculosis in less than a year against the up to two-year regimen recommended by the […]
The following is a guest post by Ruth Ashton of MEASURE Evaluation CHAPEL HILL, NC―A new study released today in the Lancet’s eClinicalMedicine shows that routine […]